Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma

Article Abstract:

Pamidronate infusions may help reduce skeletal complications in patients with advanced multiple myeloma, a cancer of the bone marrow. The cancerous cells destroy bone tissue, a cause of fractures, pain, and deformities. Researchers measured the benefits of 90 milligrams of infused pamidronate disodium, an inhibitor of bone resorption, among 196 patients with multiple myeloma. A controlgroup of 181 patients received placebo infusions. After nine months, fewer skeletal complications and less bone pain distinguished the patients who were receiving pamidronate compared to the control group. In addition, fractures occurred later and less frequently, the quality of life improved, and the infusions were well tolerated in the pamidrone group. Two patients discontinued pamidronate therapy due to toxic side effects.

Evaluation, Bones, Prevention, Bone resorption, Fractures (Injuries), Disodium pamidronate, Pamidronate

---

A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma

Article Abstract:

Treatment with high doses of melphalan combined with bone marrow transplantation may improve response rates and survival rates in patients with myeloma. A total of 200 myeloma patients were randomly allocated to receive conventional chemotherapy or high-dose chemotherapy followed by bone marrow transplant. More patients in the chemotherapy/transplant group achieved complete or very good partial responses compared to those in the conventional chemotherapy group. Survival rates were significantly higher in those who achieved a complete or very good partial response.

Bone marrow, Bone marrow transplantation

---

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma

Article Abstract:

The efficacy for lenalidomide plus dexamethasone in the treatment of relapsed or refractory multiple myeloma is determined. Lenalidomide plus dexamethasone is found to be better than high-dose dexamethasone alone.

Health aspects, Drug therapy, Comparative analysis, Drug therapy, Combination, Combination drug therapy, Dexamethasone, Clinical report, Lenalidomide

Similar abstracts:

• Abstracts: Effects of a potent and selective PPAR-[alpha] agonist in patients with atherogenic dyslipidemia or hypercholesterolemia: Two randomized controlled trials
• Abstracts: Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus. Effects of rosiglitazone on the risk of myocardial infraction and death from cardiovascular causes
• Abstracts: Improving practice in wound care for patients with dementia
• Abstracts: A new doctor in the house: ethical issues in hospitalist systems. A framework for health care organizations to develop and evaluate a safety scorecard
• Abstracts: A framework for your development. Broaden your skills with volunteering

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.